Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy

Cell

Volumn 171, Issue 7, 2017, Pages 1678-1691.e13

  Palmer, Adam C ^a   Sorger, Peter K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

cancer; clinical trials; combination therapy; drug synergy; mathematical modeling; patient derived tumor xenograft; pharmacology; systems biology; tumor heterogeneity

Indexed keywords

ALPELISIB; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BINIMETINIB; CARBOPLATIN; CETUXIMAB; CRIZOTINIB; CYCLOPHOSPHAMIDE; DABRAFENIB; DOCETAXEL; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IPILIMUMAB; IRINOTECAN; NIVOLUMAB; OLAPARIB; OXALIPLATIN; PACLITAXEL; PEMETREXED; PERTUZUMAB; RIBOCICLIB; TRAMETINIB; TRASTUZUMAB;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MODEL; CANCER PATIENT; CHEMOSENSITIVITY; CLINICAL EFFECTIVENESS; CROSS RESISTANCE; DRUG APPROVAL; DRUG EFFICACY; DRUG POTENTIATION; FOOD AND DRUG ADMINISTRATION; HUMAN; MELANOMA; METASTATIC BREAST CANCER; MONOTHERAPY; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; STOMACH CANCER; TREATMENT RESPONSE; TUMOR XENOGRAFT; ANIMAL; BIOLOGICAL VARIATION; CANCER TRANSPLANTATION; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; DRUG INTERACTION; DRUG RESISTANCE; IMMUNOTHERAPY; NEOPLASM; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL VARIATION, INDIVIDUAL; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; HETEROGRAFTS; HUMANS; IMMUNOTHERAPY; NEOPLASM TRANSPLANTATION; NEOPLASMS;

EID: 85038028982     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2017.11.009     Document Type: Article

References (51)

1. Aghajanian, C., Blank, S.V., Goff, B.A., Judson, P.L., Teneriello, M.G., Husain, A., Sovak, M.A., Yi, J., Nycum, L.R., OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J. Clin. Oncol. 30 (2012), 2039–2045.
2. Berenbaum, M.C., What is synergy?. Pharmacol. Rev. 41 (1989), 93–141.
3. Berge, E.M., Lu, X., Maxson, D., Barón, A.E., Gadgeel, S.M., Solomon, B.J., Doebele, R.C., Varella-Garcia, M., Camidge, D.R., Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer. Clin. Lung Cancer 14 (2013), 636–643.
4. Bhang, H.E., Ruddy, D.A., Krishnamurthy Radhakrishna, V., Caushi, J.X., Zhao, R., Hims, M.M., Singh, A.P., Kao, I., Rakiec, D., Shaw, P., et al. Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Nat. Med. 21 (2015), 440–448.
5. Bokemeyer, C., Van Cutsem, E., Rougier, P., Ciardiello, F., Heeger, S., Schlichting, M., Celik, I., Köhne, C.H., Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur. J. Cancer 48 (2012), 1466–1475.
6. Bookman, M.A., Brady, M.F., McGuire, W.P., Harper, P.G., Alberts, D.S., Friedlander, M., Colombo, N., Fowler, J.M., Argenta, P.A., De Geest, K., et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J. Clin. Oncol. 27 (2009), 1419–1425.
7. Bozic, I., Reiter, J.G., Allen, B., Antal, T., Chatterjee, K., Shah, P., Moon, Y.S., Yaqubie, A., Kelly, N., Le, D.T., et al. Evolutionary dynamics of cancer in response to targeted combination therapy. eLife, 2, 2013, e00747.
8. Brugarolas, J., Clark, J.W., Chabner, B., Using “rationally designed drugs” rationally. Lancet 361 (2003), 1758–1759.
9. Burger, R.A., Sill, M.W., Monk, B.J., Greer, B.E., Sorosky, J.I., Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 25 (2007), 5165–5171.
10. Cardoso, F., Bedard, P.L., Winer, E.P., Pagani, O., Senkus-Konefka, E., Fallowfield, L.J., Kyriakides, S., Costa, A., Cufer, T., Albain, K.S., ESO-MBC Task Force. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J. Natl. Cancer Inst. 101 (2009), 1174–1181.
11. DeRose, Y.S., Wang, G., Lin, Y.C., Bernard, P.S., Buys, S.S., Ebbert, M.T., Factor, R., Matsen, C., Milash, B.A., Nelson, E., et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat. Med. 17 (2011), 1514–1520.
12. Ducreux, M., Mitry, E., Ould-Kaci, M., Boige, V., Seitz, J.F., Bugat, R., Breau, J.L., Bouché, O., Etienne, P.L., Tigaud, J.M., et al. Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. Ann. Oncol. 15 (2004), 467–473.
13. Eder, J.P., Hait, W.N., Frei, E. 3rd, Grochow, L.B., Principles of Dose, Schedule, and Combination Chemotherapy. Hong, W.K., (eds.) Holland Frei Cancer Medicine 8, 2010, People's Medical Pub. House.
14. Fisher, R.I., Gaynor, E.R., Dahlberg, S., Oken, M.M., Grogan, T.M., Mize, E.M., Glick, J.H., Coltman, C.A. Jr., Miller, T.P., Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N. Engl. J. Med. 328 (1993), 1002–1006.
15. Frei, E. 3rd, Curative cancer chemotherapy. Cancer Res. 45 (1985), 6523–6537.
16. Frei, E. 3rd, Freireich, E.J., Gehan, E., Pinkel, D., Holland, J.F., Selawry, O., Haurani, F., Spurr, C.L., Hayes, D.M., James, G.W., et al. Studies of Sequential and Combination Antimetabolite Therapy in Acute Leukemia: 6-Mercaptopurine and Methotrexate. Blood 18 (1961), 431–454.
17. Frei, E. 3rd, Karon, M., Levin, R.H., Freireich, E.J., Taylor, R.J., Hananian, J., Selawry, O., Holland, J.F., Hoogstraten, B., Wolman, I.J., et al. The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Blood 26 (1965), 642–656.
18. Freireich, E.J., Gehan, E., Frei, E. 3rd, Schroeder, L.R., Wolman, I.J., Anbari, R., Burgert, E.O., Mills, S.D., Pinkel, D., Selawry, O.S., et al. The Effect of 6-Mercaptopurine on the Duration of Steroid-induced Remissions in Acute Leukemia: A Model for Evaluation of Other Potentially Useful Therapy. Blood 21 (1963), 699–716.
19. Fuentes, G., Scaltriti, M., Baselga, J., Verma, C.S., Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism. Breast Cancer Res., 13, 2011, R54.
20. Gaddum, J.H., Pharmacology. First Edition, 1940, Oxford University Press.
21. Gandhi, L., Drappatz, J., Ramaiya, N.H., Otterson, G.A., High-dose pemetrexed in combination with high-dose crizotinib for the treatment of refractory CNS metastases in ALK-rearranged non-small-cell lung cancer. J. Thorac. Oncol. 8 (2013), e3–e5.
22. Gao, H., Korn, J.M., Ferretti, S., Monahan, J.E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat. Med. 21 (2015), 1318–1325.
23. Giantonio, B.J., Catalano, P.J., Meropol, N.J., O'Dwyer, P.J., Mitchell, E.P., Alberts, S.R., Schwartz, M.A., Benson, A.B. 3rd, Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 25 (2007), 1539–1544.
24. Goel, S., Duda, D.G., Xu, L., Munn, L.L., Boucher, Y., Fukumura, D., Jain, R.K., Normalization of the vasculature for treatment of cancer and other diseases. Physiol. Rev. 91 (2011), 1071–1121.
25. Hafner, M., Niepel, M., Chung, M., Sorger, P.K., Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nat. Methods 13 (2016), 521–527.
26. Hamid, O., Robert, C., Daud, A., Hodi, F.S., Hwu, W.J., Kefford, R., Wolchok, J.D., Hersey, P., Joseph, R.W., Weber, J.S., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369 (2013), 134–144.
27. Hidalgo, M., Amant, F., Biankin, A.V., Budinská, E., Byrne, A.T., Caldas, C., Clarke, R.B., de Jong, S., Jonkers, J., Mælandsmo, G.M., et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 4 (2014), 998–1013.
28. Jonas, O., Landry, H.M., Fuller, J.E., Santini, J.T. Jr., Baselga, J., Tepper, R.I., Cima, M.J., Langer, R., An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors. Sci. Transl. Med., 7, 2015, 284ra57.
29. Karapetis, C.S., Khambata-Ford, S., Jonker, D.J., O'Callaghan, C.J., Tu, D., Tebbutt, N.C., Simes, R.J., Chalchal, H., Shapiro, J.D., Robitaille, S., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359 (2008), 1757–1765.
30. Kim, K.B., Kefford, R., Pavlick, A.C., Infante, J.R., Ribas, A., Sosman, J.A., Fecher, L.A., Millward, M., McArthur, G.A., Hwu, P., et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J. Clin. Oncol. 31 (2013), 482–489.
31. Klinghoffer, R.A., Bahrami, S.B., Hatton, B.A., Frazier, J.P., Moreno-Gonzalez, A., Strand, A.D., Kerwin, W.S., Casalini, J.R., Thirstrup, D.J., You, S., et al. A technology platform to assess multiple cancer agents simultaneously within a patient's tumor. Sci. Transl. Med., 7, 2015, 284ra58.
32. Kummar, S., Chen, H.X., Wright, J., Holbeck, S., Millin, M.D., Tomaszewski, J., Zweibel, J., Collins, J., Doroshow, J.H., Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nat. Rev. Drug Discov. 9 (2010), 843–856.
33. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Cowey, C.L., Lao, C.D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N. Engl. J. Med. 373 (2015), 23–34.
34. Law, L.W., Effects of combinations of antileukemic agents on an acute lymphocytic leukemia of mice. Cancer Res. 12 (1952), 871–878.
35. Liu, J.F., Barry, W.T., Birrer, M., Lee, J.M., Buckanovich, R.J., Fleming, G.F., Rimel, B., Buss, M.K., Nattam, S., Hurteau, J., et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 15 (2014), 1207–1214.
36. Long, G.V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J.J., et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N. Engl. J. Med. 371 (2014), 1877–1888.
37. Malaney, P., Nicosia, S.V., Davé, V., One mouse, one patient paradigm: New avatars of personalized cancer therapy. Cancer Lett. 344 (2014), 1–12.
38. Moore, M.J., Goldstein, D., Hamm, J., Figer, A., Hecht, J.R., Gallinger, S., Au, H.J., Murawa, P., Walde, D., Wolff, R.A., et al., National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25 (2007), 1960–1966.
39. Oza, A.M., Cibula, D., Benzaquen, A.O., Poole, C., Mathijssen, R.H., Sonke, G.S., Colombo, N., Špaček, J., Vuylsteke, P., Hirte, H., et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 16 (2015), 87–97.
40. Perez, E.A., Ballman, K.V., Mashadi-Hossein, A., Tenner, K.S., Kachergus, J.M., Norton, N., Necela, B.M., Carr, J.M., Ferree, S., Perou, C.M., et al. Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial. J. Natl. Cancer Inst., 109, 2016.
41. Polyzos, A., Kosmas, C., Tsavaris, N., Markopoulos, C., Kalahanis, N., Papadopoulos, O., Arnaouti, T., Sfikakis, P.P., Doxorubicin plus Ifosfamide as Salvage Treatment for Patients with Advanced Breast Cancer Refractory to Epirubicin plus Cyclophosphamide. Clin. Drug Investig. 19 (2000), 349–355.
42. Pritchard, J.R., Bruno, P.M., Gilbert, L.A., Capron, K.L., Lauffenburger, D.A., Hemann, M.T., Defining principles of combination drug mechanisms of action. Proc. Natl. Acad. Sci. USA 110 (2013), E170–E179.
43. Renouf, D.J., Tang, P.A., Hedley, D., Chen, E., Kamel-Reid, S., Tsao, M.S., Tran-Thanh, D., Gill, S., Dhani, N., Au, H.J., et al. A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer. Eur. J. Cancer 50 (2014), 1909–1915.
44. Shaw, A.T., Kim, D.W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.J., De Pas, T., Besse, B., Solomon, B.J., Blackhall, F., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 368 (2013), 2385–2394.
45. Slamon, D.J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344 (2001), 783–792.
46. Sledge, G.W., Neuberg, D., Bernardo, P., Ingle, J.N., Martino, S., Rowinsky, E.K., Wood, W.C., Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J. Clin. Oncol. 21 (2003), 588–592.
47. Steel, G.G., Cell loss as a factor in the growth rate of human tumours. Eur. J. Cancer 3 (1967), 381–387.
48. Swain, S.M., Baselga, J., Kim, S.B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.M., Schneeweiss, A., Heeson, S., et al., CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N. Engl. J. Med. 372 (2015), 724–734.
49. Tubiana, M., Tumor cell proliferation kinetics and tumor growth rate. Acta Oncol. 28 (1989), 113–121.
50. Undevia, S.D., Gomez-Abuin, G., Ratain, M.J., Pharmacokinetic variability of anticancer agents. Nat. Rev. Cancer 5 (2005), 447–458.
51. Vogel, C.L., Cobleigh, M.A., Tripathy, D., Gutheil, J.C., Harris, L.N., Fehrenbacher, L., Slamon, D.J., Murphy, M., Novotny, W.F., Burchmore, M., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20 (2002), 719–726.